The Role of Bordetella Infections in Patients with Acute Exacerbation of Chronic Bronchitis by Bonhoeffer, J. et al.
Infection 33 · 2005 · No. 1 © URBAN & VOGEL 13
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Acute Exacerbation of Chronic Bronchitis
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Abstract
Background: Acute exacerbations of chronic bronchitis 
(AECB) are associated with a variety of viral and bacterial 
infectious agents, some of which are potentially preventable 
by immunization. Bordetella pertussis, which causes 
whooping cough, has not been studied in this context. We 
aimed to assess the role of Bordetella infections in patients 
with AECB.
Patients and Methods: Patients with AECB, who presented 
to participating private practices in Basel, Switzerland, 
between October 2000 and June 2002, were evaluated by 
a standardized questionnaire, nasopharyngeal swabs for 
culture (Bordetella spp.), and PCR (Bordetella spp. and 
selected other respiratory pathogens) and paired blood 
samples for serologic diagnosis of Bordetella infection.
Results: A total of 26 patients (34-86 years of age) were 
recruited. All culture and PCR samples were negative. 
Serology revealed Bordetella infection in eight (31%) 
patients. Duration of cough was shorter in patients with 
Bordetella infection compared to those without Bordetella 
infection (mean 15 days vs 41 days, p = 0.04). Cough ≥ 21 
days duration was present in three (43%) of seven patients 
with evidence of Bordetella infection compared to 17 (94%) 
of 18 controls (p = 0.012). Progression to convalescence 
from initial to follow-up visit after 4-6 weeks was compa-
rable between both groups.
Conclusion: Bordetella infections appear to play a 
significant role in AECB and preventive measurements such 
as immunization with acellular pertussis vaccines should be 
considered. Extended investigations are necessary to confirm 
our preliminary and provocative findings.
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Introduction
The mechanisms leading to acute exacerbations of chronic 
bronchitis (AECB) have been controversially discussed. 
While viral agents may initially play an important role, 
colonizing bacteria then proliferate and aggravate symp-
toms. The use of antibiotics in this context remains a topic 
of debate. New data indicate the importance of recently 
acquired strains of bacteria for the induction of AECB [1]. 
The potential role of Bordetella pertussis in AECB has not 
been studied so far. 
Pertussis (or whooping cough) is caused by the gram-
negative bacterium B. pertussis or, less commonly, Borde-
tella parapertussis [2]. The disease not only occurs in unim-
munized children and in infants too young to be immunized 
but also in adolescents and adults with waning immunity 
[3, 4]. Complications such as encephalopathy may affect 
patients at any age [5, 6]. Although most countries have im-
plemented pertussis component vaccines in their immuni-
zation programs for children, booster doses in adolescence 
are recommended only in a few countries [2]. The concept 
of general booster doses in adults is currently under discus-
sion [7]. As an alternative, booster immunizations could 
be considered for selected adults at high risk for pertus-
sis. The aim of the present study was to assess the role of 
Bordetella infections in adults with chronic bronchitis, who 
suffer from frequent exacerbations and therefore form a 
potential target group for booster immunization. 
Patients and Methods
Study Population 
Patients with an acute exacerbation of AECB, presenting to one 
of 17 general practitioners or internists in Basel, Switzerland, were 
eligible to participate in this study. The diagnosis of chronic bron-
chitis was based on a history of cough with expectoration for ≥ 3 
months/year in two consecutive years [8].
Exacerbation was defined as increasing expectoration and/or 
change of sputum color with or without increased frequency or 
severity of cough and elevated body temperature (≥ 38 °C) [9]. 
Patients were excluded in the presence of known HIV infection, 
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if they had received any immunoglobulins within 3 months prior 
to the date of inclusion or during the study period, or in case of 
participation in any other study. The study protocol was approved 
by the medical faculty’s ethics committee, University of Basel, 
Switzerland, and was performed in accordance with good clinical 
practices (GCP) guidelines. Written informed consent was obtai-
ned from all patients.
Clinical Information
At three visits (initial presentation, 7–14 days and 4–6 weeks later) 
the severity of AECB was assessed by a standardized questionnaire 
including known exposition to B. pertussis, clinical variables of 
chronic bronchitis such as the date of first diagnosis, active smoking, 
number of pack-years (average packs/day multiplied by years of 
smoking), current number of cigarettes per day, number of exacer-
bations in the last 12 months, use of antibiotics in the last 3 months, 
and current medication. To assess the clinical features of the cur-
rent exacerbation, increased cough, duration of cough, paroxysms, 
productive cough, increased expectoration, change in sputum color, 
whooping, post-tussive vomiting, and similar previous exacerba-
tions were recorded. Dyspnea was assessed by the conventional 
performance scale in which level 1 represents the least and level 5 
the most severe impact on everyday performance [10].
Specimen Collection and Laboratory Procedures 
Two nasopharyngeal swabs (NPS) and a venous blood sample 
were taken at the initial visit and a second blood specimen was 
obtained at the 4–6 week follow-up visit. One NPS (in modified 
Regan-Lowe transport medium) was used for culture of B. per-
tussis or B. parapertussis in Stainer-Scholte broth and on Regan-
Lowe agar in the microbiological laboratory of the University 
Children’s Hospital in Basel. Conventional bacterial cultures were 
not performed. The second NPS (in sterile 0.9% NaCl) was used 
for PCR analyses, which were performed in laboratory facilities 
separate from those for bacterial cultures. The methods have been 
described in detail [11–13]. In addition, aliquots of NPS for PCR 
analyses were sent to the microbiological laboratory, University 
Children’s Hospital Kiel, Germany, for single-tube multiplex re-
verse transcription PCR [14]. Primers for DNA sequences of My-
coplasma pneumoniae, Chlamydia pneumoniae, adeno-, entero-, 
parainfluenza type 1, parainfluenza type 3, influenza-A, influenza- 
B, and respiratory-syncytial virus were used.
Serological analyses were performed at the German National 
Reference Center for Bordetella Infections (Institute of Hygiene 
and Laboratory Medicine, Krefeld). IgG and IgA antibodies 
against filamentous hemagglutinin (FHA) and pertussis toxin 
(PT) were determined by a well-established, in-house ELISA [15, 
16]. Paired sera were analyzed in the same test. An internal refer-
ence was used for constructing the reference line, where Food and 
Drug Administration – Center for Biologics Evaluation and Con-
trol (FDA-CBER) reference sera 3 and 4 served as controls. The 
minimal level of detection was 1.9–3.0 U/ml and was arbitrarily 
set as 2.0 U/ml for all methods. Intra-assay serology varied from 
3.0% (anti-FHA IgA) to 14.0% (anti-PT IgA) [16, 17]. No other 
serological tests were performed.
Case Definitions
A diagnosis of pertussis was made in the presence of a positive 
bacterial culture and/or PCR and/or serological evidence of B. 
pertussis infection. Serological evidence of infection was assumed 
in the presence of a significant increase or decrease in at least two 
of the four antibody assays of which at least one had to be directed 
against PT (IgG and/or IgA). Alternatively, antibody concentra-
tions above the 95th percentile (established by use of a healthy 
control group) in at least two of the four assays were considered 
diagnostic, where at least one had to be directed against PT in an 
acute or convalescent serum specimen. The control group consis-
ted of healthy unvaccinated adults, i.e. regular blood donors and 
military staff.
A diagnosis of parapertussis was made in the presence of a 
positive culture and/or a positive PCR for B. parapertussis and 
absence of a significant antibody response to PT. 
If culture and PCR were negative and significant antibody 
responses were directed at FHA only, it was assumed that a recent 
contact to either B. pertussis or B. parapertussis was possible. 
A twofold increase or decrease of antibody concentrations 
was considered significant. Single high antibody concentrations 
were defined as follows (U/ml): IgG-PT ≥ 38, IgA-PT ≥ 12, IgG-
FHA ≥ 86, IgA-FHA ≥ 42.
Statistics
Statistical analysis was performed using SPSS 11.0.0 (SPSS Inc. 
2001, Chicago, IL). Independent proportions were compared by 
Fisher’s exact test. Student's t test was used for comparison of 
means. Friedman test was used for comparison of ordinal data in 
dependent groups. P < 0.05 was considered significant. 
Results
Basic Characteristics
26 patients with 26 episodes of AECB were enrolled be-
tween October 2000 and June 2002 and 25 (96%) of them 
completed follow-up. One patient was not available for 
the 4–6 week visit because of poor compliance. The mean 
age of patients was 68 years and 25 of 26 patients were 40 
years of age or older (median 71, range 34–86). Mean dura-
tion of chronic bronchitis was 12 years (median 10, range 
2–36) with a mean of two acute exacerbations (median 
1, range 0–5) during the last 12 months. Twelve patients 
(46%) were active smokers with a mean of 35 pack-years 
(median 40, range 1–70). None of the patients had a his-
tory of known recent exposure to B. pertussis. The mean 
interval between onset of cough and presentation was 7 
days (median 5, range –21). 20 patients (77%) recalled at 
least one prior similar cough episode. Eight patients (35%) 
had received antibiotic treatment within the last 3 months. 
The mean interval between last dose of antibiotic and study 
enrolment was 20 days (median 21, range 1–38).
Laboratory Findings
None of the 26 NPS cultures revealed growth of B. pertussis 
or B. parapertussis.  In addition, all 26 PCR samples were 
negative for Bordetella spp. or any other infectious agent 
identified by multiplex PCR. For ELISA, 25 paired serum 
specimens and a further single acute-phase serum speci-
men were available. The results are shown in table 1. As 
can be seen, five (19%) episodes were classified as B. per-
tussis infection and for three (12%) episodes a diagnosis of 
“either B. pertussis or B. parapertussis infection” was made. 
In all of these eight episodes, Bordetella infection was de-
tected by elevated antibody concentrations in either the 
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acute or convalescent serum specimen, whereas a signifi-
cant increase or decrease of antibody concentrations was 
not observed in any of the paired specimens (Table 1).
Clinical Findings
There was no significant difference between patients with 
or without evidence for Bordetella infection concerning 
age, characteristics of underlying disease and clinical pre-
sentation of the current exacerbation. However, total du-
ration of cough (documented in 25 patients) was shorter 
in patients with Bordetella infection compared to those 
without Bordetella infection: mean 15 days (95% CI: 7–23) 
vs 41 days (95% CI: 17–64), p = 0.04. Furthermore, a to-
tal duration of cough ≥ 21 days during 
AECB was present in three (43%) of 
seven patients with evidence of Borde-
tella infection compared to 17 (94%) of 
18 patients without Bordetella infection 
(p = 0.012; Table 2). Interestingly, four 
of five  patients (80%) with a duration 
of cough between 7 and 21 days dur-
ing AECB had Bordetella infections, 
whereas only three of 20 patients (15%) 
with cough > 21 days duration had evi-
dence for Bordetella infection.
Mean values of the dyspnea per-
formance scale decreased from visit to 
visit in both groups, indicating similar 
progression to convalescence: Borde-
tella infection vs no Bordetella infection: 
initial visit 3.0 (CI: 1.9–4.0) vs 2.5 (CI: 
1.95–3.05); 7–14 days 2.4 (CI: 1.4–3.4) 
vs 2.0 (CI: 1.6–2.4); 4–6 weeks 2.1 (CI: 
1.2–3.0) vs 1.8 (CI: 1.3–2.4). There 
were no hospital admissions or 
other complications reported in 
any study subject.
      Discussion
Here we present findings from 
a pilot study on the role of Bor-
detella infection in patients with 
acute exacerbations of chronic 
bronchitis. To our knowledge, 
this has not been studied before 
and our results indicate that Bor-
detella infections may play a sig-
nificant role in these patients. 
We found evidence of Borde-
tella infection in eight (31%) of 26 
AECB by demonstration of ele-
vated antibody concentrations in 
acute serum specimens. In three 
patients the antibody pattern (i.e. 
response to FHA only) did not 
allow us to discern B. pertussis 
from B. parapertussis infection. Furthermore, we cannot 
rule out that antibody responses against FHA were caused 
by cross-reaction to antigens from microorganisms other 
than Bordetella [18]. However, there were five patients 
(19%) with a significant antibody response to PT, which is 
specific for B. pertussis infection. Interestingly, in a recent 
study of 155 health-care workers at a German children’s 
hospital with regular contact to patients, 6% were found 
to have elevated IgG and/or IgA antibodies against PT or 
FHA by using the same serological methods [17]. Apply-
ing the definitions by DeMelker et al. [19] (relying on a 
single IgG anti-PT > 100 EU/ml) or Birkebaek et al. [20] 
(relying on a single Ig Ganti-PT > 123 EU/ml) to our data, 
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Patient           Acute serumb             Convalescent serumc Interpretation of 
                       serology results
                   PTa                    FHAa                  PT                FHA 
 IgG   IgA IgG   IgA IgG   IgA   IgG   IgA
1    9   3  149d 135 12  6 243 115 Pertussis or parapertussis
2  10 < 2 179  94 12 < 2 186 112 Pertussis or parapertussis
3  38   2 146  55 - - -  -  Pertussis or parapertussis
4  31 16 199 133 32 13 188 138 Pertussis
5  10 40   73 113  7 33 79 111 Pertussis
6 79   3   42  39 68  5 52 43 Pertussis
7           371 90 118 607 288 38 124 571 Pertussis
8 12 16 106  34 17 20 72 47 Pertussis
a U/ml; FHA: filamentous hemagglutinin; PT: pertussis toxin; b venous blood sample taken at the 
initial presentation of the patient with cough illness; c venous blood sample taken 4–6 weeks af-
ter the initial presentation of the patient with cough illness; d figures in bold indicate significant 
high concentrations (U/ml): IgG-PT ≥ 38, IgA-PT ≥ 12, IgG-FHA ≥ 86, IgA-FHA ≥ 42 
Table 1
Antibody concentrationsa demonstrating Bordetella infection in eight patients with acute 
exacerbation of chronic bronchitis.
Finding   Pertussis/parapertussis   Others
 N/total (%)     N/total (%) 
Any increased cough      8/8 (100)     18/18 (100)
    Productive   8/8 (100) 17/18 (94)
    Paroxysms   8/8 (100) 15/18 (83)
    Whooping 3/8 (38)  3/18 (17)
    Post-tussive vomiting 1/8 (12)  6/18 (33)
Any prior similar cough  7/8 (87)  13/18 (72) 
Duration of cough ≥ 21d  3/7 (43)b  17/18 (94)b
Duration of paroxysms ≥ 21d 2/7 (28)  7/18 (39)
Dyspnea 3/8 (38) 13/18 (72)
Fever 3/8 (38)  5/18 (28)
a One patient with evidence for infection with B. pertussis or B. parapertussis was lost for 
follow-up at 4–6 weeks; b p = 0.012   
Table 2
Presence of clinical findings in 26 patientsa with acute exacerbation of chronic 
bronchitis depending on evidence for infection with B. pertussis or B. parapertussis.
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only one patient would have fulfilled the serological crite-
ria for acute B. pertussis infection [19, 20]. In contrast to 
this and other previously published serological definitions 
for recent exposure to B. pertussis, which are based solely 
on IgG antibody analyses [19-21], our definition includes 
IgG and IgA antibody tests. Importantly, four of the five 
patients fulfilling our definition of B. pertussis infection do 
this based on elevated anti-PT IgA antibodies.
Also, we cannot exclude the possibility that our refer-
ence values, deriving from adults without chronic bronchitis, 
are different from those in patients with chronic bronchitis. 
Overall, however, the proportion of B. pertussis infections 
in our study is in line with the 20–25% found among other-
wise healthy adults with cough illnesses [3, 22–24].
Antibody determinations in convalescent specimens 
demonstrated little changes compared to those in acute 
specimens and did not contribute to the diagnostic sensitiv-
ity. This is a plausible finding, because adults are likely to 
have had previous infection with B. pertussis (or B. para-
pertussis) and secondary immune responses cause a rapid 
increase in antibody concentrations [25]. Furthermore, spe-
cific IgA and IgG serum antibodies do significantly decrease 
again within a few months after acute infection [26]. Thus, 
our data confirm that a single acute serum sample probably 
is sufficient for serological diagnosis of pertussis in adults.
It is not surprising that direct demonstration of Bor-
detella spp. by PCR or culture was not possible in any of 
the eight Bordetella infections in this study. In a recent 
study from Canada, 442 adolescents and adults > 12 years 
of age with cough of 7–56 days duration were evaluated. 
Only four (0.9%) of them were positive for B. pertussis 
by culture or PCR, whereas 84 (19.1%) had serologically 
diagnosed B. pertussis infection [27]. This means that B. 
pertussis was detected in only one of 20 patients with per-
tussis. Also, in other previous investigations on pertussis 
in adults, 21–65% of serologically diagnosed Bordetella in-
fections were associated with positive PCR and/or culture 
[28–32]. This considerable variability in direct demonstra-
tion of the organism from nasopharyngeal specimens may 
be due to inhomogeneous sampling techniques among dif-
ferent investigators, which may also have contributed to 
the negative finding in our study. 
Thus, our data confirm that serological analysis is of 
paramount importance for diagnosis of pertussis not only 
in otherwise healthy adults, but also in those with AECB, 
whereas culture and PCR lack sensitivity.
To our surprise, patients with Bordetella infection had 
a shorter duration of cough compared to those with cough 
of unknown etiology. This is a new and provocative find-
ing. It can be explained by the fact that illness caused by B. 
pertussis in adults is usually due to reinfection, which seems 
to occur frequently in otherwise healthy adults [4, 33]. Our 
findings indicate that this is probably also the case in pa-
tients with chronic bronchitis. We offer the hypothesis that 
partial immunity acquired from prior infection with B. per-
tussis leads to comparatively mild symptoms during rein-
fections. The atypical presentation of Bordetella infections 
under these circumstances makes specific microbiological 
investigations necessary to establish the diagnosis. This is 
of clinical relevance, because (1) treatment with macrolides 
should be initiated to avoid transmission to other suscep-
tible individuals, especially young infants [34], and (2) no 
further diagnostic procedures are usually necessary.
The overall similar clinical presentation of AECB 
associated with Bordetella infection compared to non-
Bordetella infection in our study is of no surprise and has 
also been observed in patients without underlying pulmo-
nary disease [24, 35, 36]. However, given the frequency of 
cough exacerbations in patients with chronic bronchitis, 
our finding of Bordetella infection in up to 30% of these 
episodes is relevant. In light of these data, pertussis im-
munization could significantly decrease the morbidity of 
patients with chronic bronchitis. Acellular pertussis vac-
cines, with proven excellent immunogenicity and safety 
in adolescents and adults, would be available for this pur-
pose [2, 37].
Our study has limitations. Most importantly, despite 
our repeated efforts to remind participating physicians of 
the purpose and goal of this study, recruitment of patients 
with AECB was lower than expected. Obviously, tight 
schedules in their offices caused prolonged intervals of 
enrollment inactivity. One could argue that therefore our 
study sample might be biased towards recruiting patients 
with suspected pertussis. However, based on the unspecific 
clinical findings in our patients and the fact that exposure 
to B. pertussis was denied by all patients, we believe there 
is no indication for such a bias.
Therefore, this present study should be considered as 
a pilot project which provides preliminary and provocative 
evidence on the role of Bordetella infection in adults with 
acute exacerbations of chronic bronchitis. Confirmative, 
extended investigations are necessary. 
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